Mounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes — not for weight loss. Mounjaro is a dual GIP/GLP-1 receptor agonist; Ozempic is a GLP-1 receptor agonist. In the only head-to-head trial comparing the two molecules, SURMOUNT-5, tirzepatide produced more weight loss than semaglutide (−20.2% vs −13.7% over 72 weeks); in the diabetes head-to-head, SURPASS-2, tirzepatide cut A1C more at every dose. But Ozempic's semaglutide carries cardiovascular outcome data Mounjaro doesn't yet have. If you want one quick rule: for diabetes plus the most weight loss, tirzepatide tends to win on the data; for diabetes plus established heart disease, semaglutide has the proven MACE benefit.

The decision matrix — find your situation:

• •If you have type 2 diabetes and want the most weight loss alongside glucose control → the data favors Mounjaro (tirzepatide) → ask your doctor; if cash-paying, compounded tirzepatide via Gala $149/mo or TrimRx $179/mo.
• •If you have type 2 diabetes plus established heart disease → Ozempic (semaglutide) — it's the molecule with the SELECT cardiovascular outcome data → covered by most diabetes insurance plans.
• •If you want weight loss and do NOT have diabetes → neither Mounjaro nor Ozempic is FDA-approved for you. Their on-label sister brands are → Zepbound (tirzepatide) and Wegovy (semaglutide).
• •If insurance denies you and you're paying cash → compounded tirzepatide from Gala $149/mo or TrimRx $179/mo; compounded semaglutide also from TrimRx; or the cheapest GLP-1 at $146/mo via Yucca Health. Compare every cash path on /cheapest.
• •If you can't or won't inject → oral tirzepatide gum via Embody, or see all GLP-1 pill options.
• •Not sure which fits? Take the 2-minute match quiz or estimate your real out-of-pocket on the cost calculator.

This is the question patients actually take to their doctor: which one is better, Mounjaro or Ozempic? Below we walk through what each drug is, how the mechanisms differ, the head-to-head trial data for weight loss and A1C, the cardiovascular picture, the off-label weight-loss reality, and every cost path — verified against FDA labeling and the published NEJM trials. For the generic-molecule view, see semaglutide vs tirzepatide.

What Each Drug Actually Is

Mounjaro is the brand name for tirzepatide, made by Eli Lilly. It received FDA approval in May 2022 as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It's a once-weekly subcutaneous injection available in doses from 2.5 mg (starter) up to 15 mg.

Ozempic is the brand name for semaglutide, made by Novo Nordisk. It received FDA approval in December 2017 for type 2 diabetes, with later expansions to reduce cardiovascular risk in adults with T2D and known heart disease, and to slow chronic kidney disease progression in T2D. It's a once-weekly injection available in 0.25 mg (starter), 0.5 mg, 1 mg, and 2 mg.

So the real four-way landscape is: Mounjaro and Zepbound are both tirzepatide (diabetes vs. weight loss); Ozempic and Wegovy are both semaglutide (diabetes vs. weight loss). This guide focuses on the two diabetes brands patients name most often — Mounjaro vs. Ozempic — but the head-to-head molecule data applies to their weight-loss twins too.

Mechanism: Why Mounjaro Hits Two Receptors and Ozempic Hits One

This is the core biological difference and the reason the trial numbers come out the way they do.

Ozempic (semaglutide) is a single-agonist — it mimics one gut hormone, GLP-1 (glucagon-like peptide-1). GLP-1 lowers blood sugar by stimulating insulin release when glucose is high, slows how fast your stomach empties, and acts on appetite centers in the brain to reduce hunger.

Mounjaro (tirzepatide) is a dual agonist — it mimics GLP-1 and a second gut hormone, GIP (glucose-dependent insulinotropic polypeptide), in a single molecule. The theory, supported by the trial data, is that engaging both incretin pathways improves glucose handling and appetite suppression more than GLP-1 alone. Tirzepatide is the first dual GIP/GLP-1 receptor agonist the FDA approved.

Weight-Loss Head-to-Head: SURMOUNT-5

For years, comparing the two was guesswork because no trial pitted them directly against each other. That changed with SURMOUNT-5, the first head-to-head trial, published in the New England Journal of Medicine in 2025.

SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The result: tirzepatide produced −20.2% mean body-weight reduction versus −13.7% for semaglutide — a 6.5 percentage-point advantage that was statistically significant (p<0.001). In absolute terms, that was roughly 22.8 kg of weight lost on tirzepatide versus 15.0 kg on semaglutide.

Participants on tirzepatide were also more likely to hit the bigger milestones — losing at least 10%, 15%, 20%, and 25% of their body weight — and saw a larger reduction in waist circumference (−18.4 cm vs −13.0 cm).

Diabetes Head-to-Head: SURPASS-2 (A1C and Glucose)

Because both Mounjaro and Ozempic are diabetes drugs, the most relevant direct comparison for their actual approved use is SURPASS-2, published in NEJM in 2021. It randomized 1,879 adults with type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg, or to semaglutide 1 mg, over 40 weeks.

From a baseline A1C of 8.28%, all three tirzepatide doses lowered A1C more than semaglutide 1 mg: −2.09% (5 mg), −2.37% (10 mg), and −2.46% (15 mg) for tirzepatide, versus −1.86% for semaglutide 1 mg. Body-weight reduction followed the same pattern — tirzepatide 15 mg cut about 12.4 kg versus 6.2 kg for semaglutide 1 mg.

The Cardiovascular Picture: Where Ozempic Has the Edge

Weight and A1C aren't the whole story. The hardest clinical endpoint is whether a drug prevents heart attacks, strokes, and cardiovascular death — and here semaglutide currently has more proven data than tirzepatide.

The SELECT trial, published in NEJM in November 2023, followed 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a mean follow-up of about 40 months. (SELECT used the 2.4 mg Wegovy dose, but it's the same molecule that's in Ozempic.) Ozempic's own label also carries a cardiovascular risk-reduction indication for people with type 2 diabetes and known heart disease, based on the earlier SUSTAIN-6 data.

Tirzepatide's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is the study that will eventually settle whether it matches or beats semaglutide on hard heart endpoints. Until that reads out and is reflected on the label, semaglutide is the molecule with the stronger published cardiovascular evidence base — a genuine reason a cardiologist might prefer it for the right patient, even though tirzepatide wins on weight and A1C.

The Off-Label Weight-Loss Reality

Here's what happens in practice. Many people without diabetes are prescribed Ozempic or Mounjaro off-label for weight loss. Off-label prescribing is legal — a doctor can prescribe any FDA-approved drug for a use they judge appropriate. But it has two real consequences.

• •Insurance usually won't cover it. If you don't have type 2 diabetes, your plan will typically deny Mounjaro or Ozempic because you're using it outside its approved indication. The on-label weight-loss brands — Zepbound and Wegovy — are the ones insurers evaluate for obesity coverage.
• •The dose ceiling is different. Ozempic maxes at 2 mg; Wegovy goes to 2.4 mg (and a higher-dose version exists). For tirzepatide, both Mounjaro and Zepbound reach 15 mg, so the dose gap is smaller on that side.

If weight loss is your goal and you don't have diabetes, the cleaner path is the on-label twin: Zepbound vs Mounjaro for tirzepatide, or Wegovy vs Zepbound and Ozempic vs Wegovy for the semaglutide side. That keeps you on-label and gives you the best shot at coverage.

Cost Paths: What You'll Actually Pay

Brand Mounjaro and Ozempic both carry list prices around $1,000+ per month. With type 2 diabetes and commercial insurance plus a manufacturer savings card, your out-of-pocket can drop dramatically — often to a low double-digit copay if your plan covers it. Without diabetes, expect a denial for the brand diabetes drug, which is why so many people end up paying cash or routing to compounded options.

If you're paying cash, the compounded versions of the same molecules are where the real savings live:

• •Compounded tirzepatide (the Mounjaro molecule), microdose: Gala $149/mo — a lower-dose, lower-cost on-ramp to tirzepatide.
• •Compounded tirzepatide AND semaglutide, plus brand options: TrimRx $179/mo — covers both molecules under one program.
• •Multiple compounded formats: SkinnyRx — five compounded options if you want flexibility on format.
• •Cheapest GLP-1 overall: Yucca Health $146/mo.
• •No-injection tirzepatide: Embody oral tirzepatide gum for people who can't or won't use needles.

To see every program ranked and priced, start with our best GLP-1 providers and the cheapest GLP-1 options. For the full pricing breakdown by drug, see the GLP-1 cost guide, tirzepatide cost, and the compounded tirzepatide guide. Run your specific numbers on the cost calculator.

Side Effects: How They Compare

Both drugs share the GLP-1 side-effect profile, and the most common adverse events are gastrointestinal — nausea, diarrhea, vomiting, and constipation — concentrated during the dose-escalation phase. Slow, gradual dose increases are the main way doctors limit them.

In SURMOUNT-5, gastrointestinal adverse events leading people to stop treatment were actually somewhat more common with semaglutide (5.6%) than tirzepatide (2.7%) — a useful counterpoint to the assumption that the more potent drug is always harder to tolerate. Individual tolerance varies a lot.

Both carry a boxed warning for the risk of thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. For a practical playbook on managing day-to-day symptoms, see our GLP-1 side effects management guide.

Frequently Asked Questions

The Bottom Line

If you have type 2 diabetes and want maximum weight loss with your glucose control, the head-to-head data favors Mounjaro (tirzepatide). If you have diabetes plus established heart disease, Ozempic (semaglutide) has the proven cardiovascular outcome evidence. If you don't have diabetes and you're chasing weight loss, neither one is your on-label answer — look at Zepbound and Wegovy instead, or route to a compounded cash-pay option if coverage is the wall you're hitting.

Start with the best GLP-1 providers, find your lowest price on /cheapest, or take the 2-minute match quiz to see which program fits your situation.

Sources

• •SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity (NEJM 2025;393(1):26-36)
• •SURMOUNT-5 summary — American College of Cardiology Journal Scan
• •SURPASS-2: Tirzepatide vs Semaglutide in T2D (NEJM 2021) — Eli Lilly press release
• •SELECT: Semaglutide and Cardiovascular Outcomes (NEJM 2023)
• •Mounjaro (tirzepatide) FDA prescribing information
• •Ozempic (semaglutide) FDA prescribing information